|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||23.25 - 23.25|
|52 Week Range||17.41 - 23.74|
|Beta (5Y Monthly)||0.28|
|PE Ratio (TTM)||29.72|
|Forward Dividend & Yield||0.16 (0.68%)|
|Ex-Dividend Date||May 12, 2021|
|1y Target Est||11.49|
With vaccine rollouts through Q2, Thermo Fisher's (TMO) Life-Science Solutions segment is likely to have registered top-line contributions from vaccine and therapy production supplies.
It's a lot easier when you buy companies that have a history of great performance and a clear path to years of profitable growth ahead. Revenue growth has exceeded 25% every year for the past decade, averaging 29% over the past three-year and five-year periods. The combination has turned Veeva into a free cash flow champion.
SAN DIEGO, July 15, 2021 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2021 on Thursday, August 5, 2021, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss these results. Other forward-looking and material information may also be discussed during this webcast. Earnings webcast details: Location: http://investor.resmed.comDat